Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
REVENUE, NET        
Products $ 83,914 $ 48,966 $ 169,654 $ 59,400
Services 160,360 286,077
Total revenues, net 244,274 48,966 455,731 59,400
COST OF REVENUE        
Total costs of revenue 98,373 42,400 198,170 60,158
GROSS MARGIN (LOSS) 145,901 6,566 257,561 (758)
EXPENSES        
Sales and marketing 219,809 111,393 329,435 455,437
General and administrative 707,192 188,052 1,151,241 395,198
Depreciation and amortization 39,747 292 79,496 585
TOTAL OPERATING EXPENSES 966,748 299,737 1,560,172 851,220
OPERATING LOSS (820,847) (293,171) (1,302,611) (851,978)
Other Income (Expense)        
Unrealized gain on equity investments 245,834 404,763
Change in fair value of derivative 4,254 4,254
Interest Expense (38,637) (66,422) (64,801) (68,301)
Total other (expense), net (34,383) 179,412 (60,547) 336,462
NET LOSS (855,230) (113,759) (1,363,158) (515,516)
Less: Net loss attributable to non controlling interest 77,484 3,336 161,515 9,592
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP. $ (777,746) $ (110,423) $ (1,201,643) $ (505,924)
LOSS PER COMMON SHARE $ (0.06) $ (0.01) $ (0.09) $ (0.05)
WEIGHTED AVERAGE SHARES OUTSTANDING        
Basic and diluted 13,465,791 10,677,110 13,456,451 10,617,332